Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc. Show more

Location: 5005 McConnell Avenue, Los Angeles, CA, 90066, United States | Website: https://www.armatapharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

243.8M

52 Wk Range

$0.90 - $16.34

Previous Close

$6.71

Open

$6.58

Volume

97,326

Day Range

$6.53 - $7.20

Enterprise Value

406.7M

Cash

14.76M

Avg Qtr Burn

-6.754M

Insider Ownership

69.29%

Institutional Own.

2.09%

Qtr Updated

09/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.